|
|
|
Insider
Information: |
Celgene Corp /de/ |
Relationship: |
|
City: |
Summit |
State: |
NJ |
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
9 |
|
Direct
Shares |
56,020,938 |
|
Indirect Shares
|
6,630,042 |
|
|
Direct
Value |
$1,800,019,242 |
|
|
Indirect Value
|
$359,152,850 |
|
|
Total
Shares |
62,650,980 |
|
|
Total
Value |
$2,159,172,091 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
0
|
0
|
Stock
price went up :
|
0
|
0
|
Stock
price went down : |
0
|
0
|
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
Percentage
Gain/Loss : |
0.0%
|
0.0%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Casi Pharmaceuticals Inc |
CASI |
10% Owner |
2005-03-31 |
23,750,000 |
2005-03-31 |
0 |
Premium* |
|
Epizyme, Inc. |
EPZM |
10% Owner |
2014-02-10 |
3,674,640 |
2013-06-05 |
0 |
Premium* |
|
Acceleron Pharma Inc |
XLRN |
|
2019-01-18 |
6,824,685 |
2013-09-24 |
0 |
Premium* |
|
Alliqua BioMedical Inc |
ALQA |
10% Owner |
2017-04-11 |
7,342,377 |
|
0 |
Premium* |
|
Globeimmune Inc |
GBIM |
10% Owner |
2014-07-08 |
400,670 |
2014-07-08 |
600,670 |
Premium* |
|
Crispr Therapeutics Ag |
CRSP |
10% Owner |
2016-10-24 |
4,834,980 |
2018-11-21 |
4,173,019 |
Premium* |
|
Jounce Therapeutics Inc |
JNCE |
10% Owner |
2017-02-01 |
3,456,463 |
2017-02-01 |
0 |
Premium* |
|
Agios Pharmaceuticals Inc |
AGIO |
10% Owner |
2017-04-24 |
4,010,926 |
2017-04-24 |
1,856,353 |
Premium* |
|
Sutro Biopharma Inc |
STRO |
|
2018-10-01 |
1,726,197 |
2018-10-01 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
48 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 1 of 2
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
STRO |
Sutro Biopharma Inc |
|
|
2018-10-01 |
4 |
A |
$0.00 |
$0 |
D/D |
1,726,197 |
1,726,197 |
0 |
- |
|
XLRN |
Acceleron Pharma Inc |
|
|
2019-01-18 |
4 |
B |
$43.00 |
$30,366,858 |
D/D |
706,206 |
6,824,685 |
0.01 |
- |
|
CASI |
Casi Pharmaceuticals Inc |
10% Owner |
|
2005-03-31 |
4 |
OE |
$1.50 |
$10,500,000 |
D/D |
7,000,000 |
23,750,000 |
|
- |
|
EPZM |
Epizyme, Inc. |
10% Owner |
|
2013-06-05 |
4 |
A |
$0.00 |
$0 |
D/D |
3,267,974 |
3,267,974 |
0 |
- |
|
EPZM |
Epizyme, Inc. |
10% Owner |
|
2013-06-05 |
4 |
B |
$15.00 |
$999,990 |
D/D |
66,666 |
3,334,640 |
2.45 |
- |
|
XLRN |
Acceleron Pharma Inc |
10% Owner |
|
2013-09-24 |
4 |
A |
$0.00 |
$0 |
D/D |
57,899 |
515,774 |
0 |
- |
|
XLRN |
Acceleron Pharma Inc |
10% Owner |
|
2013-09-24 |
4 |
B |
$15.00 |
$10,000,005 |
D/D |
666,667 |
3,172,887 |
2.45 |
- |
|
XLRN |
Acceleron Pharma Inc |
10% Owner |
|
2013-09-24 |
4 |
A |
$0.00 |
$0 |
D/D |
2,448,321 |
2,506,220 |
0 |
- |
|
ALQA |
Alliqua BioMedical Inc |
10% Owner |
|
2013-11-18 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
1,672,474 |
|
- |
|
XLRN |
Acceleron Pharma Inc |
10% Owner |
|
2014-01-28 |
4 |
B |
$50.00 |
$15,000,000 |
D/D |
300,000 |
3,472,887 |
2.45 |
- |
|
EPZM |
Epizyme, Inc. |
10% Owner |
|
2014-02-10 |
4 |
B |
$29.25 |
$9,945,000 |
D/D |
340,000 |
3,674,640 |
2.45 |
- |
|
ALQA |
Alliqua BioMedical Inc |
10% Owner |
|
2014-04-14 |
4 |
B |
$7.00 |
$5,000,002 |
D/D |
714,286 |
2,386,760 |
2.45 |
- |
|
XLRN |
Acceleron Pharma Inc |
10% Owner |
|
2014-05-05 |
4 |
B |
$42.86 |
$47,146,000 |
D/D |
1,100,000 |
4,572,887 |
2.45 |
- |
|
GBIM |
Globeimmune Inc |
10% Owner |
|
2014-07-08 |
4 |
A |
$0.00 |
$0 |
D/D |
400,670 |
400,670 |
0 |
- |
|
GBIM |
Globeimmune Inc |
10% Owner |
|
2014-07-08 |
4 |
B |
$10.00 |
$2,000,000 |
I/I |
200,000 |
600,670 |
1.5 |
- |
|
ALQA |
Alliqua BioMedical Inc |
10% Owner |
|
2015-05-04 |
4 |
B |
$4.55 |
$2,999,997 |
D/D |
659,340 |
3,046,100 |
2.45 |
- |
|
XLRN |
Acceleron Pharma Inc |
10% Owner |
|
2016-01-11 |
4 |
B |
$40.00 |
$32,000,000 |
D/D |
800,000 |
5,372,887 |
2.45 |
- |
|
CRSP |
Crispr Therapeutics Ag |
10% Owner |
|
2016-10-24 |
4 |
A |
$0.00 |
$0 |
D/D |
4,034,830 |
4,034,830 |
0 |
- |
|
CRSP |
Crispr Therapeutics Ag |
10% Owner |
|
2016-10-24 |
4/A |
B |
$14.00 |
$11,202,100 |
I/I |
800,150 |
4,834,980 |
1.5 |
- |
|
CRSP |
Crispr Therapeutics Ag |
10% Owner |
|
2016-10-24 |
4/A |
A |
$0.00 |
$0 |
I/I |
4,034,830 |
4,034,830 |
0 |
- |
|
CRSP |
Crispr Therapeutics Ag |
10% Owner |
|
2016-10-24 |
4 |
B |
$14.00 |
$11,202,100 |
D/D |
800,150 |
4,834,980 |
2.45 |
- |
|
JNCE |
Jounce Therapeutics Inc |
10% Owner |
|
2017-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
2,831,463 |
2,831,463 |
0 |
- |
|
JNCE |
Jounce Therapeutics Inc |
10% Owner |
|
2017-02-01 |
4 |
B |
$16.00 |
$10,000,000 |
D/D |
625,000 |
3,456,463 |
2.45 |
- |
|
ALQA |
Alliqua BioMedical Inc |
10% Owner |
|
2017-02-27 |
4 |
B |
$0.50 |
$2,000,000 |
D/D |
4,000,000 |
7,046,100 |
2.45 |
- |
|
ALQA |
Alliqua BioMedical Inc |
10% Owner |
|
2017-04-11 |
4 |
A |
$0.00 |
$0 |
D/D |
296,277 |
7,342,377 |
0 |
- |
|
48 Records found
|
|
Page 1 of 2 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|